Todorovic
VS, Vasovic M, Andric M, Todorovic L, Kokovic V. Efficacy
of fentanyl transdermal patch in pain control after lower third molar surgery:
A preliminary study.
Med
Oral Patol Oral Cir Bucal. 2016 Sep 1;21
(5):e621-5.
doi:10.4317/medoral.21161
http://dx.doi.org/doi:10.4317/medoral.21161
|
1.
Meechan JG, Seymour RA. The use of third molar surgery in clinical
pharmacology. Br J Oral Maxillofac Surg. 1993;31:360-5. |
|
|
|
|
|
2.
Seymour RA, Walton JG. Pain control after third molar surgery. Int J Oral
Surg. 1984;13:457-85. |
|
|
|
|
|
3.
Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of
life and cancer pain: satisfaction and side effects with transdermal fentanyl
versus oral morphine. J Clin Oncol. 1998;16:1588-93. |
|
|
|
|
|
4.
Isiordia-Espinoza MA, Sanchez-Prieto M, Tobias-Azua F, Reyes-Garcia JG.
Pre-emptive analgesic effectiveness of meloxicam versus tramadol after
mandibular third molar surgery: a pilot study. J Oral Maxillofac Surg.
2012;70:31-6. |
|
|
|
|
|
5.
Mattia C, Coluzzi F. Acute postoperative pain management: focus on
iontophoretic transdermal fentanyl. Ther Clin Risk Manag. 2007;3:19-27. |
|
|
|
|
|
6.
Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the
management of pain. Drugs. 2010;70:57-72. |
|
|
|
|
|
7.
Lotsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of
non-intravenous formulations of fentanyl. Clin Pharmacokinet. 2013;52:23-36. |
|
|
|
|
|
8.
Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to
transdermal fentanyl: a multicenter study in patients with cancer pain. Pain.
1996;64:527-34. |
|
|
|
|
|
9.
Fine PG. Fentanyl in the treatment of cancer pain. Semin Oncol.
1997;24(5Suppl):S16-27. |
|
|
|
|
|
10.
Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D. Transdermal
fentanyl in the long-term treatment of cancer pain: a prospective study of 50
patients with advanced cancer of the gastrointestinal tract or the head and
neck region. Pain. 1997;69:191-8. |
|
|
|
|
|
11.
Viscusi ER, Siccardi M, Damaraju CV, Hewitt DJ, Kershaw P. The safety and
efficacy of fentanyl iontophoretic transdermal system compared with morphine
intravenous patient-controlled analgesia for postoperative pain management:
an analysis of pooled data from three randomized, active-controlled clinical
studies. Anesth Analg. 2007;105:1428-36. |
|
|
|
|
|
12.
Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J
Med Toxicol. 2009;5:230-41. |
|
|
|
|
|
13.
Larsen RH, Nielsen F, Sorensen JA, Nielsen JB. Dermal penetration of
fentanyl: inter- and intraindividual variations. Pharmacol Toxicol.
2003;93:244-8. |
|
|
|
|
|
14.
Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, et al.
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl
after repeated 72-hour transdermal applications in cancer pain patients. Ther
Drug Monit. 2005;27:491-8. |
|
|
|
|
|
15.
Gupta SK, Southam M, Gale R, Hwang SS. System functionality and
physicochemical model of fentanyl transdermal system. J Pain Symptom Manage.
1992;7(3 Suppl):S17-26. |
|
|
|
|
|
16.
Chelly JE. An iontophoretic, fentanyl HCl patient-controlled transdermal
system for acute postoperative pain management. Expert Opin Pharmacother.
2005;6:1205-14. |
|
|
|
|
|
17.
Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled
transdermal fentanyl hydrochloride vs intravenous morphine pump for
postoperative pain: a randomized controlled trial. JAMA. 2004;291:1333-41. |
|